TGA / PMDA / NMPA · Asia-Pacific
clostridium — TGA / PMDA / NMPA regulatory status
clostridium regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 17 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| M602011084 | Phase 3 | Merz Therapeutics | 2024-515682-34-00 |
| M602011085 | Phase 3 | Merz Therapeutics | 2024-515715-22-00 |
| SER-109 | Phase 3 | Seres Therapeutics | NCT03183128 |
| CP101 | Phase 2 | Finch Therapeutics Group | NCT03497806 |
| Clostridium Butyricum Tablets | Phase 2 | First People's Hospital | NCT06696742 |
| Full Spectrum Microbiota | Phase 2 | Finch Therapeutics Group | NCT03110133 |
| Ibezapolstat | Phase 2 | Acurx Pharmaceuticals | NCT04247542 |
| Ibezapolstat | Phase 2 | Acurx Pharmaceuticals | NCT07513285 |
| Ridinilazole | Phase 2 | Summit Therapeutics | NCT02784002 |
| SER-109 | Phase 2 | Seres Therapeutics | NCT02437487 |
| SMT19969 | Phase 2 | Summit Therapeutics | NCT02092935 |
| VP20621 | Phase 2 | Takeda | NCT01259726 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12390496 | Methods for treating ulcerative colitis | US |
| 2025235515 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS AND IMPROVED DRYING PROCESSES | US |
| 2025111258 | COMPOSITIONS DE SÉROTYPE A DE NEUROTOXINE DE CLOSTRIDIUM BOTULINUM ET PROCÉDÉS DE FILTRATION AMÉLIORÉS | WO |
| 12285447 | Methods and compositions for treating ulcerative colitis | US |
| 12144800 | Inhibiting germination of Clostridium perfringens spores to reduce necrotic enteritis | US |
| 12036225 | Use of ibezapolstat to promote microbiome health | US |
| 11865145 | Compositions and methods for maintaining and restoring a healthy gut barrier | US |
| 11857629 | Methods and compositions for self-regulated release of active pharmaceutical ingredient | US |
| 11730775 | Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof | US |
| 11723885 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | US |
| 11623930 | Imidazodiazepinediones and methods of use thereof | US |
| 11554114 | Methods and compositions for self-regulated release of active pharmaceutical ingredients | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of clostridium?
clostridium currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get clostridium regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to clostridium?
This spoke lists 17 published programs associated with clostridium in our pipeline index.